Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with classical Hodgkin lymphoma, confirmed by a tissue sample (biopsy).
• People who are 12 years of age or older.
• People who have received one or two prior treatment regimens (chemotherapy or immunotherapy), and fall into one of two groups:
  • Group A: People who received the drug brentuximab as part of their first treatment, but have never received a checkpoint inhibitor drug (such as nivolumab or pembrolizumab).
  • Group B: People who received one checkpoint inhibitor drug (nivolumab or pembrolizumab) during either their first or second treatment, but have never received brentuximab.
• Radiation given alongside the first treatment, or to consolidate a second treatment, counts as part of that treatment course rather than as a separate regimen.
• People who have not previously had a stem cell or bone marrow transplant (either their own cells or a donor's cells).
• People who are reasonably physically active and able to carry out daily activities (as measured by standard medical scales — confirm with trial site for exact requirements).
• People who have at least one measurable tumour or affected lymph node larger than 1.5 cm.
• People whose side effects from previous treatments have mostly resolved to a mild level or better, including any nerve-related symptoms such as tingling or numbness.
• People whose blood counts and organ function results are within acceptable ranges, based on blood tests taken within 28 days of starting the trial (confirm with trial site for exact values).
• People living with HIV may be eligible, provided they have no co-infection with hepatitis B or C, have a sufficiently healthy immune system, show no signs of drug-resistant HIV, have an undetectable viral load while on HIV treatment, and have been seen by an infectious disease specialist within the past 90 days.
• Women who could become pregnant must have a negative pregnancy test before starting treatment.
• Women who could become pregnant, and men participating in the trial, must agree to use reliable contraception during the trial and for 6 months after finishing treatment.
• People who have finished all previous cancer treatments at least 2 weeks before starting the trial.
• People with a known heart condition or history of heart-related treatment must have a heart function assessment, and meet at least a certain level of heart function on a standard medical scale (confirm with trial site for exact classification).
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures.
• Adults aged 18 and over must provide signed informed consent. For patients aged 12–17, a parent or legal guardian must provide consent, and the young person must also agree to take part according to their institution's guidelines.

Who may not be able to join:

• People with a history of another cancer, unless it was a type of skin cancer (basal cell or squamous cell) or early-stage cervical cancer that was adequately treated, or another cancer that has been in remission for 2 or more years and is not expected to affect life expectancy.
• People who have had chemotherapy or radiotherapy within the 2 weeks before entering the trial, or who still have side effects from previous treatment above a mild level.
• People with an active autoimmune disease, or a history of certain autoimmune conditions such as autoimmune hepatitis, pituitary inflammation, kidney inflammation, lung inflammation, or bowel inflammation.
• People whose lymphoma has spread to the central nervous system (the brain or spinal cord).
• People who test positive for hepatitis B or hepatitis C.
• People with an active or ongoing infection, or other active serious health conditions such as significant heart failure, unstable chest pain, irregular heartbeat, or a mental health or personal situation that would make it difficult to follow the trial requirements.

Important: Always verify eligibility with the trial site directly before applying.